SANUWAVE’s CE-marked orthoPACE devices sold fewer units in 2012, partially due to the European economic downturn, according to the release.
The company’s research and development cost $1.8 million over the past year compared with $2.7 million in 2011, a 35 percent decrease, due to lower clinical results expenses.
More Articles on Devices:
7 New Orthopedic Device Launches & Releases
Amedica Valeo Interbody Fusion Device Hits 10k Implantations
Baptist Medical Center Acquires Renaissance Spine System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.